Kymab is discovering and developing fully human monoclonal antibody therapeutics using our pioneering Kymouse™ platform. We are building a rich pipeline of assets in four therapeutic spaces: immuno-oncology, inflammation, haematology and infectious diseases.

The Kymouse strains have more base-pairs of the human immunoglobulin genes than any other model. Their performance is exceptional: virtually every mouse responds to challenge, producing high-titre polyclonal antibodies to a variety of antigens including highly conserved human antigens.

Company Growth (employees)
Babraham, GB
Size (employees)
130 (est)+2%
Kymab was founded in 2009 and is headquartered in Babraham, GB

Key People/Management at Kymab

BBS Anne Hyland

BBS Anne Hyland

Chief Financial Officer
Glenn Friedrich

Glenn Friedrich

Chief Operating Officer
Sonia Quaratino

Sonia Quaratino

Chief Medical Officer
FRS Allan Bradley

FRS Allan Bradley

Chief Scientific Officer
Arndt Schottelius

Arndt Schottelius

Executive Vice President, R&D
Nigel Clark

Nigel Clark

Senior Vice President, Business Development
EPA Jasper Clube

EPA Jasper Clube

Senior Vice President, Intellectual Property and Chief Patent Counsel

Kymab Office Locations

Kymab has offices in Babraham and Taipei
Babraham, GB (HQ)
Meditrina Building, 260 Babraham Research Campus
Show all (2)

Kymab Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$220.4 m

Latest funding size

$100 m

Time since last funding

about 1 year


Kymab's latest funding round in November 2016 was reported to be $100 m. In total, Kymab has raised $220.4 m

Kymab Financials

GBPFY, 2011FY, 2012

Current Assets


Total Assets


Additional Paid-in Capital


Total Equity

    Y, 2012

    Financial Leverage

    1 x
    Show all financial metrics

    Kymab's Web-traffic and Trends

    Kymab Company Life and Culture

    You may also be interested in